The site of the Media Sphera Publishers contains materials intended solely for healthcare professionals.
By closing this message, you confirm that you are a certified medical professional or a student of a medical educational institution.

Login
EN
+7 (495) 482-4118
+7 (495) 482-4329
+8 800 250-18-12
  • (toll-free number for subscriptions)
    Mon-Fri from 10 a.m. to 6 p.m.

  • © 1998-2026
+7 (495) 482-43-29
EN
All journals
Journal
Year
Year
Search result: 0

Voznyuk I.A.

Zaharov V.V.

Sechenov First Moscow State Medical University (Sechenov University)

Tanashyan M.M.

Research Center of Neurology

Putilina M.V.

Pirogov Russian National Research Medical University

Zhivolupov S.A.

Kirov Military Medical Academy

Vorobeva O.V.

Chuvash state university named after I.N. Ulyanov

Granovskaya M.A.

Systems Biology Ireland of the University College Dublin (Ireland) EMBL/Uni Heidelberg

Danilov An.B.

Institute of Professional Education of the Sechenov First Moscow State Medical University

Danilov Al.B.

Sechenov First Moscow State Medical University (Sechenov University)

Shishkova V.N.

National Medical Research Center for Therapy and Preventive Medicine Federal State Budgetary Institution the Ministry of Health of Russia;
A.I. Yevdokimov Moscow State University of Medicine and Dentistry Federal State Budgetary Educational Institution of Higher Education

Pizova N.V.

Yaroslavl State Medical University

Litvinenko I.A.

Kirov Military Medical Academy

Kuznetsova P.I.

Research Center of Neurology

Raskurazhev A.A.

Scientific Center of Neurology

Butsev V.V.

City Hospital No. 4

Prospects of use of research results for drugs with anitihypoxic and antioxidative properties in neuroprotective treatment strategies (Opinion of the Council of Experts dated 26 March 2022)

Authors:

Voznyuk I.A., Zaharov V.V., Tanashyan M.M., Putilina M.V., Zhivolupov S.A., Vorobeva O.V., Granovskaya M.A., Danilov An.B., Danilov Al.B., Shishkova V.N., Pizova N.V., Litvinenko I.A., Kuznetsova P.I., Raskurazhev A.A., Butsev V.V.

More about the authors

Journal: S.S. Korsakov Journal of Neurology and Psychiatry. 2022;122(7): 51‑55

DOI: 10.17116/jnevro202212207151

Read: 2566 times

Contact the author
Table of contents

PROSPECTS OF USE OF RESEARCH RESULTS FOR DRUGS WITH ANITIHYPOXIC AND ANTIOXIDATIVE PROPERTIES IN NEUROPROTECTIVE TREATMENT STRATEGIES (OPINION OF THE COUNCIL OF EXPERTS DATED 26 MARCH 2022)
PROSPECTS OF USE OF RESEARCH RESULTS FOR DRUGS WITH ANITIHYPOXIC AND ANTIOXIDATIVE PROPERTIES IN NEUROPROTECTIVE TREATMENT STRATEGIES (OPINION OF THE COUNCIL OF EXPERTS DATED 26 MARCH 2022)

To cite this article:

Voznyuk IA, Zaharov VV, Tanashyan MM, et al. Prospects of use of research results for drugs with anitihypoxic and antioxidative properties in neuroprotective treatment strategies (Opinion of the Council of Experts dated 26 March 2022). S.S. Korsakov Journal of Neurology and Psychiatry. 2022;122(7):51‑55. (In Russ.)
https://doi.org/10.17116/jnevro202212207151

Подписка 2026 Журнал неврологии и психиатрии им. С.С. Корсакова (S.S. Korsakov Journal of Neurology and Psychiatry)
МСФ на ЯМ
Использование инфографики авторами научных работ
Close metadata
Recommended articles:
The main mechanisms of deve­lopment of cognitive impairment. S.S. Korsakov Journal of Neurology and Psychiatry. 2025;(4-2):13-18
Cognitive impairment in patients with multiple scle­rosis. S.S. Korsakov Journal of Neurology and Psychiatry. 2025;(4-2):67-73
Cognitive impairment after major surgical operations. S.S. Korsakov Journal of Neurology and Psychiatry. 2025;(4-2):74-80
Analysis of cognitive status in patients with different noso­logies and clinical variants of very late mani­festing schi­zophreniform psychosis. S.S. Korsakov Journal of Neurology and Psychiatry. 2025;(4-2):88-93
The known and new ideas about the mechanism of action and the spectrum of effe­cts of Mexi­dol. S.S. Korsakov Journal of Neurology and Psychiatry. 2025;(5):22-33
Therapeutic pote­ntial of quercetin and its deri­vatives against COVID-19. S.S. Korsakov Journal of Neurology and Psychiatry. 2025;(5):44-50
Prevalence and characteristics of risk factors for cere­brovascular disease in overweight. S.S. Korsakov Journal of Neurology and Psychiatry. 2025;(5):118-124
Cere­brolysin with repe­rfusion therapy in ischemic stroke: a prospective analysis of multimodal brain imaging data from the CERE­HETIS trial. S.S. Korsakov Journal of Neurology and Psychiatry. 2025;(6):84-98
Mathematical mode­ling of outcomes in patients with clinical combination of ischemic stroke and COVID-19 complicated by multiple organ failure. Russian Journal of Anesthesiology and Reanimatology. 2025;(3):42-49
Socio-economic damage caused by elevated low-density lipo­protein cholesterol levels. Medi­cal Technologies. Asse­ssment and Choice. 2025;(2):88-98
Abstract:

Cerebrovascular diseases are one of the main causes of death and permanent disability. Effective and timely neuroprotective therapy can reduce the burden of cerebrovascular disease. The possibilities of neuroprotection as a method of prevention and medical rehabilitation of acute and chronic cerebrovascular diseases are addressed.

Keywords:

ischemic stroke
cognitive impairment
asthenic syndrome
asthenia
neuroprotection
neurorecovery
neuroactivation
ethylmethylhydroxypyridine succinate
meldonium

Authors:

Voznyuk I.A.

Zaharov V.V.

Sechenov First Moscow State Medical University (Sechenov University)

Tanashyan M.M.

Research Center of Neurology

Putilina M.V.

Pirogov Russian National Research Medical University

Zhivolupov S.A.

Kirov Military Medical Academy

Vorobeva O.V.

Chuvash state university named after I.N. Ulyanov

Granovskaya M.A.

Systems Biology Ireland of the University College Dublin (Ireland) EMBL/Uni Heidelberg

Danilov An.B.

Institute of Professional Education of the Sechenov First Moscow State Medical University

Danilov Al.B.

Sechenov First Moscow State Medical University (Sechenov University)

Shishkova V.N.

National Medical Research Center for Therapy and Preventive Medicine Federal State Budgetary Institution the Ministry of Health of Russia;
A.I. Yevdokimov Moscow State University of Medicine and Dentistry Federal State Budgetary Educational Institution of Higher Education

Pizova N.V.

Yaroslavl State Medical University

Litvinenko I.A.

Kirov Military Medical Academy

Kuznetsova P.I.

Research Center of Neurology

Raskurazhev A.A.

Scientific Center of Neurology

Butsev V.V.

City Hospital No. 4

Received:

01.07.2022

Accepted:

01.07.2022

Close metadata

References:

  1. Ozturk S. Stroke and stroke risk factors as disease burden. Health Risk Analysis. 2021;4:146-151.  https://doi.org/10.21668/health.risk/2021.4.16
  2. Kostenko EV, Eneeva MA. Chronic cerebrovascular diseases: pathogenetic heterogeneity and therapeutic strategies. Medical Council. 2018;(18):50-55. (In Russ.). https://doi.org/10.21518/2079-701X-2018-18-50-55
  3. Semenov SE, Portnov YuM, Khromov AA, et al. The cerebral perfusion of circulation disturbances. Part II (CT- and MRI semiotics, patterns of pathological changes). Review. Complex Issues of Cardiovascular Diseases. 2017;(1):102-111. (In Russ.). https://doi.org/10.17802/2306-1278-2017-1-102-111
  4. Ischemic stroke and transient ischemic attack in adults. Clinical recommendations. 2020;207. 
  5. Pizova NV. Chronic cerebrovascular diseases: pathogenetic mechanisms, clinical manifestations, and approaches to therapy. Neurology, Neuropsychiatry, Psychosomatics. 2018;10(1):83-89. (In Russ.). https://doi.org/10.14412/2074-2711-2018-1-83-89
  6. Putilina MV. Combined therapy of cerebrovascular disorders with neuroprotectors. Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova. 2016;116(11):58-63. (In Russ.). https://doi.org/10.17116/jnevro201611611158-63
  7. Shishkova VN. New opportunities of evaluation of ischemic stroke secondary prophylaxis effectiveness in therapeutic practice. Consilium Medicum. 2019;21(2):43-7. (I Russ.).
  8. Isaikin AI, Chernyshova EA, Yakhno NN. The use of neuroprotective therapy for strokes and traumatic brain injury. Difficult Patient. 2012;11. (In Russ.). https://www.elibrary.ru/item.asp?id=18886525
  9. Dyukova GM. Asthenic syndrome: problems of diagnosis and therapy. Effective Pharmacotherapy. Neurology and Psychiatry. 2012;1:40-45. (In Russ.).
  10. Petrova LV, Kostenko EV, Eneeva MA. Asthenia and Post-COVID Syndrome: Pathogenesis, Clinical Presentations, Diagnosis, and Medical Rehabilitation. Doctor.Ru. 2021;20(9):36-42. (In Russ). https://doi.org/10.31550/1727-2378-2021-20-9-36-42
  11. Voronina TA. Mexidol: the spectrum of pharmacological effects. Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova. 2012;112(12):86-90. (In Russ.).
  12. Voronina TA. Antioxidant Mexidol. The main neuropsychotropic effects and mechanism of action. Farmateka. 2009;6:28-31. 
  13. Novikov VE, Losenkova S.O. Pharmacology of 3-oxypyridine derivatives. Reviews on Clinical Pharmacology and Drug Therapy. 2004;3(1):2-14. (In Russ.).
  14. Pozhilova EV, Novikov VE, Novikova AV. Pharmacodynamics and clinical use of drugs based on hydroxypyridine. Bulletin of the Smolensk State Medical Academy. 2013;12(3):56-66. (In Russ.).
  15. Maksimova MYu, Tanashyan MM, Fedorova TN, Guryanova O.E. Experience with Mildronate in ischemic stroke. Medica Mente. 2019;5(1)22-27. (In Russ.).
  16. Pizova NV. Experience with mildronate in cerebrovascular diseases. Medical Council. 2015;(5):14-18. (In Russ.).
  17. Logina IP, Kalvinsh IYa. Mildronate in neurology. Riga; 2012:56. (In Russ.).
  18. Report on the results of a clinical trial of a medicinal product: an open multicenter randomized study to evaluate the efficacy and safety of the use of Brainmax, a solution for intravenous and intramuscular administration (Promomed RUS LLC, Russia) in patients with ischemic stroke in the acute and early recovery period. Research protocol: No. MKI/0320-2 dated May 06, 2020. (In Russ).
  19. Report on the results of a clinical trial of a medicinal product: an open multicenter randomized study to evaluate the efficacy and safety of the use of Brainmax, a solution for intravenous and intramuscular administration (Promomed RUS LLC, Russia) in patients with ischemic stroke in the acute recovery period. Research protocol: No. MKI/0320-1 dated May 06, 2020. (In Russ).
  20. State Register of Medicines. Accessed June 22, 2022. (In Russ). https://grls.rosminzdrav.ru/Grls_View_v2.aspx?routingGuid=fc01ecf2-1722-41a7-a008-d5f1e7b354f4&t=
  21. Topuzova MP, Alekseeva TM, Panina EB, et al. NR2 antibodies as diagnostic and prognostic stroke biomarker. Arterial Hypertension. 2020;26(1):27-36. (In Russ.). https://doi.org/10.18705/1607-419X-2020-26-1-27-36
  22. Bolshakova AV, Kukanova EO, Gainullina AN, et al. Sigma-1 receptor as a potential pharmacological target for the treatment of neuropathology. St. Petersburg Polytechnical University Journal: Physics and Mathematics. 2016;1(237):48-65. 
  23. Belopasov VV, Yachou Y, Samoilova EM, et al. The Nervous System Damage in COVID-19. Journal of Clinical Practice. 2020;11(2):60-80. (In Russ.). https://doi.org/10.17816/clinpract34851
Contact the author
Email
Message
The publishing house "Media Sphere" does not provide treatment services, does not give recommendations on contacting medical institutions and specific specialists, on the prescription of medicines and dietary supplements.

Email Confirmation

An email was sent to test@gmail.com with a confirmation link. Follow the link from the letter to complete the registration on the site.

Email Confirmation

Contact us
If you have any questions, complaints or suggestions, please use this feedback form.
Email
Message
The publishing house "Media Sphere" does not provide treatment services, does not give recommendations on contacting medical institutions and specific specialists, on the prescription of medicines and dietary supplements.
Submit Application

You can become an author of one of our magazines, send a request and we will consider it in during the day.

Name
Phone
E-mail
Message
Login
Registration
E-mail
Password
Forgot Password?

Log in to the site using your account in one of the services

Password recovery
E-mail
Login
Register

We use cооkies to improve the performance of the site. By staying on our site, you agree to the terms of use of cооkies. To view our Privacy and Cookie Policy, please. click here.